You just read:

Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-0184, an Activin A Receptor Type 1 (ACVR1) Inhibitor, in Phase 1 Study of Patients with Advanced Solid Tumors

News provided by

Tolero Pharmaceuticals, Inc.

Jul 25, 2018, 08:00 ET